Nursing Issues in Prostate Cancer

  • Helen Crowe


The nursing role in prostate cancer has evolved rapidly in response to the medical and surgical advancements. Specialist nurses play a key role in the care of men with prostate cancer pre-diagnosis through to terminal care. By being involved at all stages of the disease prostate care, nurses are a valuable resource for these men and their families, providing information, education, advice, support, and nursing care.


Prostate Cancer Urinary Incontinence Prostate Specific Antigen Erectile Dysfunction Radical Prostatectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Drudge-Coates L. Prostate cancer and the principles of hormone therapy. Br J Nurs. 2005;14(7):368–75.PubMedGoogle Scholar
  2. 2.
    Tarrant C, Sinfield P, Agarwal S, Baker R. Is seeing a specialist nurse associated with positive experiences of care? The role and value of specialist nurses in prostate cancer care. BMC Health Serv Res. 2008;8:65.PubMedCrossRefGoogle Scholar
  3. 3.
    Ream E, Quennell A, Fincham L, Faithfull S, Khoo V, Wilson-Barnett J, et al. Supportive care needs of men living with prostate cancer in England: a survey. Br J Cancer. 2008;98(12):1903–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Ream E, Wilson-Barnett J, Faithfull S, Fincham L, Khoo V, Richardson A. Working patterns and perceived contribution of prostate cancer clinical nurse specialists: a mixed method investigation. Int J Nurs Stud. 2009;46(10):1345–54.PubMedCrossRefGoogle Scholar
  5. 5.
    Smith DP, Supramaniam R, King MT, Ward J, Berry M, Armstrong BK. Age, health, and education determine supportive care needs of men younger than 70 years with prostate cancer. J Clin Oncol. 2007;25(18):2560–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Madsen LT, Craig C, Kuban D. A multidisciplinary prostate cancer clinic for newly diagnosed patients: developing the role of the advanced practice nurse. Clin J Oncol Nurs. 2009;13(3):305–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Gray M, Sims T. Prostate cancer: prevention and management of localized disease. Nurse Pract. 2006;31(9):14.PubMedCrossRefGoogle Scholar
  8. 8.
    Boxhall S, Dougherty M. An evaluation of a specialist nursing role for men with prostate cancer. Urol Nurs. 2003;23(2):148–52.PubMedGoogle Scholar
  9. 9.
    Masood J, Forristal H, Cornes R, Vandal MT, Gujral SS. An audit of patient satisfaction with uro-oncology nurse specialists – a questionnaire study. Int J Urol Nurs. 2007;1(2):81–6.CrossRefGoogle Scholar
  10. 10.
    Hawes S, Malcarne V, Ko C, Sadler G, Banthuia R, Sherman S, et al. Identifying problems faced by spouses and partners of patients with prostate cancer. Oncol Nurs Forum. 2006;33(4):807–14.PubMedCrossRefGoogle Scholar
  11. 11.
    Galbraith ME, Pedro LW, Jaffe AR, Allen TL. Describing health-related outcomes for couples experiencing prostate cancer: differences and similarities. Oncol Nurs Forum. 2008;35(5):794–801.PubMedCrossRefGoogle Scholar
  12. 12.
    Crowe H, Costello AJ. Prostate cancer: perspectives on quality of life and impact of treatment on patients and their partners. Urol Nurs. 2003;23(4):279–85.PubMedGoogle Scholar
  13. 13.
    Davies N. Prostate cancer… this practice profile is based on NS395. Nurs Stand. 2008; 22(28): 59. Turner B. Diagnosis and treatment of patients with prostate cancer: the nurse’s role. Nurs Stand. 2007; 21(39): 48–56.Google Scholar
  14. 14.
    Neal DE, Donovan JL, Martin RM, Hamdy FC. Screening for prostate cancer remains controversial. Lancet. 2009;374(9700):1482–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Wong L. Where are we now with prostate cancer diagnosis? Trends Urol Men’s Health. 2010;1:18–20.CrossRefGoogle Scholar
  16. 16.
    Strief DM. An overview of prostate cancer: diagnosis and treatment. Medsurg Nurs. 2008;17(4):258.PubMedGoogle Scholar
  17. 17.
    Urological Society of Australia and New Zealand. PSA testing policy. 2009. Available from: Cited 8 Jan 2011.
  18. 18.
    Briganti A, Blute ML, Eastham JH, et al. Pelvic lymph node dissection in prostate cancer. Eur Urol. 2009;55:1251–65. Eur Urol. 2009 Dec;56(6):e53.PubMedCrossRefGoogle Scholar
  19. 19.
    The British Association of Urological Surgeons Ltd. Prostate Cancer Screening. 2010.
  20. 20.
    American Urological Association. Early Detection of Prostate Cancer Policy Statement. 2009.
  21. 21.
    Mahon SM. Evidence-based practice. Screening for prostate cancer: informing men about their options. Clin J Oncol Nurs. 2005;9(5):625–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Turner B. Diagnosis and treatment of patients with prostate cancer: the nurse’s role. Nurs Stand. 2007;21(39):48.PubMedGoogle Scholar
  23. 23.
    James N, McPhail G. The success of a nurse-led, one-stop suspected prostate cancer clinic. Cancer Nurs Pract. 2008;7(3):28–32.Google Scholar
  24. 24.
    Colella KM, DeLuca G. Shared decision making in patients with newly diagnosed prostate cancer: a model for treatment education and support. Urol Nurs. 2004;24(3):187.PubMedGoogle Scholar
  25. 25.
    O’Rourke M. The older adult with prostate cancer. In: Cope DG, Reb AM, editors. Treatment and care of the older adult with prostate cancer. Pittsburgh: Oncology Nursing Society; 2006. p. 225–49.Google Scholar
  26. 26.
    Hudak JL, McLeod DG, Brassell SA, Gant DA, Shaar S, Hudak RP, et al. The design and implementation of a multidisciplinary prostate cancer clinic. Urol Nurs. 2007;27(6):491–8.PubMedGoogle Scholar
  27. 27.
    Saca-Hazboun H. Advances in prostate cancer treatment. ONS Connect. 2008;23(9):8–12.PubMedGoogle Scholar
  28. 28.
    Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychol. 2003;22(5):443–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Ross T. Prostate cancer telephone helpline: nursing from a different perspective. Br J Nurs. 2007;16(3):161–5.PubMedGoogle Scholar
  30. 30.
    Scura KW, Budin W, Garfing E. Telephone social support and education for adaptation to prostate cancer: a pilot study. Oncol Nurs Forum. 2004;31(2):335–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Kunkel EJ, Myers RE, Lartey PL, Oyesanmi O. Communicating effectively with the patient and family about treatment options for prostate cancer. Semin Urol Oncol. 2000;18(3):233–40.PubMedGoogle Scholar
  32. 32.
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31.PubMedCrossRefGoogle Scholar
  33. 33.
    The National Comprehensive Cancer Network. Prostate cancer early detection guidelines. 2010. Available from: Accessed 8 Jan 2011.
  34. 34.
    Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum. 2003;30(2):303–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Robinson L, Hughes LC, Adler DC, Strumpf N, Grobe SJ, McCorkle R. Describing the work of nursing: the case of postsurgical nursing interventions for men with prostate cancer. Res Nurs Health. 1999;22(4):321–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Madsen LT, Ganey-Code E. Assessing and addressing erectile function concerns in patients postprostatectomy. Oncol Nurs Forum. 2006;33(2):209–11.PubMedCrossRefGoogle Scholar
  37. 37.
    Tarnhuvud M, Wandel C, Willman A. Nursing interventions to improve the health of men with prostate cancer undergoing radiotherapy: a review. Eur J Oncol Nurs. 2007;11(4):328–39.PubMedCrossRefGoogle Scholar
  38. 38.
    Zeroski D, Abel L, Butler WM, Wallner K, Merrick GS. Factors affecting patient selection for prostate brachytherapy: what nurses should know. Clin J Oncol Nurs. 2005;9(5):553–60.PubMedCrossRefGoogle Scholar
  39. 39.
    Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–62.PubMedCrossRefGoogle Scholar
  40. 40.
    Palmer MH, Fogarty LA, Somerfield MR, Powel LL. Incontinence after prostatectomy: coping with incontinence after prostate cancer surgery. Oncol Nurs Forum. 2003;30(2):229–38.PubMedCrossRefGoogle Scholar
  41. 41.
    McGlynn B, Al-Saffar N, Begg H, Gurun M, Hollins G, McPhee S, et al. Management of urinary incontinence following radical prostatectomy. Urol Nurs. 2004;24(6):475–82, 515.PubMedGoogle Scholar
  42. 42.
    Moore KN, Estey A. The early post-operative concerns of men after radical prostatectomy. J Adv Nurs. 1999;29(5):1121–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Ko WF, Sawatzky JA. Understanding urinary incontinence after radical prostatectomy: a nursing framework. Clin J Oncol Nurs. 2008;12(4):647–54.PubMedCrossRefGoogle Scholar
  44. 44.
    Talcott JA, Rieker P, Propert KJ, Clark JA, Wishnow KI, Loughlin KR, et al. Patient-reported impotence and incontinence after nerve sparing radical prostatectomy. J Natl Cancer Inst. 1997;89(15):1117–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Dorey G. Restoring pelvic floor function in men: review of RCTs. Br J Nurs. 2005;14(19):1014–8, 20–1.PubMedGoogle Scholar
  46. 46.
    Nahon I, Dorey G, Waddington G, Adams R. Systematic review of the treatment of post-prostatectomy incontinence. Urol Nurs. 2006;26(6):461–75. 82.PubMedGoogle Scholar
  47. 47.
    Zhang AY, Strauss GJ, Siminoff LA. Intervention of urinary incontinence and quality of life outcome in prostate cancer patients. J Psychosoc Oncol. 2006;24(2):17–30.PubMedCrossRefGoogle Scholar
  48. 48.
    Moses K, Wright K, Rutledge D. Managing urinary incontinence following robotic prostatectomy with systematic physical therapy. Oncol Nurs Forum. 2008;35(3):507.Google Scholar
  49. 49.
    Spickett I, Robertson J. Prostate cancer: the ongoing challenge. Prim Health Care. 2010;20(2):16–21.Google Scholar
  50. 50.
    Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007;178(2):597–601.PubMedCrossRefGoogle Scholar
  51. 51.
    Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J Urol. 2009;181(2):462–71.PubMedCrossRefGoogle Scholar
  52. 52.
    Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005;293(21):2648–53.PubMedCrossRefGoogle Scholar
  53. 53.
    Kendirci M, Bejma J, Hellstrom WJ. Update on erectile dysfunction in prostate cancer patients. Curr Opin Urol. 2006;16(3):186–95.PubMedCrossRefGoogle Scholar
  54. 54.
    Howlett K, Koetters T, Edrington J, West C, Paul S, Lee K, et al. Changes in sexual function on mood and quality of life in patients undergoing radiation therapy for prostate cancer. Oncol Nurs Forum. 2010;37(1):E58–66.PubMedCrossRefGoogle Scholar
  55. 55.
    Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbieri L, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997;158(4):1408–10.PubMedCrossRefGoogle Scholar
  56. 56.
    Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008;101(10):1279–83.PubMedCrossRefGoogle Scholar
  57. 57.
    Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int. 2010;105(1):37–41.PubMedCrossRefGoogle Scholar
  58. 58.
    Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol. 2004;45(2):123–33.PubMedCrossRefGoogle Scholar
  59. 59.
    Pace G, Del Rosso A, Vicentini C. Penile rehabilitation therapy following radical prostatectomy. Disabil Rehabil. 2010;32(14):1204–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Peltier A, van Velthoven R, Roumeguere T. Current management of erectile dysfunction after cancer treatment. Curr Opin Oncol. 2009;21(4):303–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Annon J. Behavioral Treatment of Sexual Problems: Harper & Row – Medical Department; New York: 1976;2.Google Scholar
  62. 62.
    Gallagher E, Gapstur R. Hormone-refractory prostate cancer: a shifting paradigm in treatment. Clin J Oncol Nurs. 2006;10(2):233–40.PubMedCrossRefGoogle Scholar
  63. 63.
    Matthews PA. Hormone ablation therapy: lightening the load for today’s prostate cancer patient. Urol Nurs. 2007;27(Suppl):3–11.PubMedGoogle Scholar
  64. 64.
    Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, et al. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer. Urology. 2009;73(3):635–40.PubMedCrossRefGoogle Scholar
  65. 65.
    Levine GN, D’Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194–201.PubMedCrossRefGoogle Scholar
  66. 66.
    Shroder FH, Collette L, De Reijke TM. Prostate cancer treated by anti-androgens: is sexual function preserved? Br J Cancer. 2000;82:283–90.CrossRefGoogle Scholar
  67. 67.
    Weingard KK. Nursing implications of androgen deprivation therapy-associated bone loss. Urol Nurs. 2006;26(4):261–9. quiz 70.PubMedGoogle Scholar
  68. 68.
    Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 2009;12(2):198–203.PubMedCrossRefGoogle Scholar
  69. 69.
    Galvao DA, Taaffe DR, Spry N, Newton RU. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(4):340–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Drudge-Coates L. Bone health: the effect of androgen deprivation therapy in prostate cancer patients. Int J Urol Nurs. 2007;1(1):18–26.CrossRefGoogle Scholar
  71. 71.
    Doggrell S. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Rev Anticancer Ther. 2009;9(9):1211–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Osborne S. Prostate cancer with bone metastasis: an overview of pain assessment and management. Int J Urol Nurs. 2008;2(3):125–33.CrossRefGoogle Scholar
  73. 73.
    Drudge-Coates L, Rajbabu K. Diagnosis and management of malignant spinal cord compression: part 1. Int J Palliat Nurs. 2008;14(3):110–6.PubMedGoogle Scholar
  74. 74.
    Shaiova L. Difficult pain syndromes: bone pain, visceral pain, and neuropathic pain. Cancer J. 2006;12(5):330–40.PubMedCrossRefGoogle Scholar
  75. 75.
    Harris K, Chow E. Need for better documentation and definition of pain flare following external beam radiotherapy in the treatment of bone metastases. J Pain Symptom Manage. 2007;33(1):6–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169(6):2008–12.PubMedCrossRefGoogle Scholar
  77. 77.
    Saylor PJ, Smith MR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis. 2010;13(1):20–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.PubMedCrossRefGoogle Scholar
  79. 79.
    Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011;48(1):88–95.PubMedCrossRefGoogle Scholar
  80. 80.
    Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897–907.PubMedCrossRefGoogle Scholar
  81. 81.
    Doyle-Lindrud S. Implications of androgen-deprivation therapy in patients with prostate cancer: a case study. Clin J Oncol Nurs. 2006;10(5):565–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Morris M, Cruickshank S. Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses. Eur J Oncol Nurs. 2010;14(3):205–10.PubMedCrossRefGoogle Scholar
  83. 83.
    Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 2010;70(8):983–1000.PubMedCrossRefGoogle Scholar
  84. 84.
    Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–64.PubMedGoogle Scholar
  85. 85.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Australian Prostate Cancer Research Center Epworth, Department of UrologyThe Royal Melbourne HospitalParkvilleAustralia

Personalised recommendations